Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients
The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
- Lung transplant recipients and immunocompetent adults who are willing to receive a respiratory syncytial virus (RSV) vaccine will be recruited at the study hospital.
- Participants will receive a single intramuscular dose of the RSV vaccine (RSVPreF3, Arexvy®)
- Participants will be contacted by telephone on Day 7 and at the Day 30 follow-up visit after vaccination to assess adverse events.
- Immunogenicity will be evaluated before vaccination and at 1 month and 12 months after vaccination, and safety will be monitored throughout the study period.
- Changes in immune responses from pre-vaccination levels will be compared between lung transplant recipients and immunocompetent adults.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 4
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Chan Mi Lee, M.D., PhD.
- Numero di telefono: 82-2-2072-1473
- Email: heaven229@naver.com
Backup dei contatti dello studio
- Nome: Young Hoon Hwang, M.D.
- Numero di telefono: 82-2-2072-2228
- Email: hyh0307@gmail.com
Luoghi di studio
-
-
Jongno-Gu
-
Seoul, Jongno-Gu, Corea del Sud, 03080
- Reclutamento
- Seoul National University Hospital
-
Contatto:
- Nam Joong Kim, M.D., PhD.
- Numero di telefono: 82-2-2072-0835
- Email: njkmd@snu.ac.kr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria (for lung transplant recipient) :
- Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study
- Recipients of a lung transplant who are receiving immunosuppressive therapy to prevent allograft rejection.
Inclusion Criteria (for control) :
- Adults aged 60 years or older who voluntarily provide written informed consent to participate in the study.
- Individuals who do not have medical conditions associated with immunocompromise (e.g., malignancy, bone marrow transplantation, solid organ transplantation, HIV infection, or dialysis) and have not received ongoing chemotherapy, radiation therapy, immunosuppressive therapy, or immunomodulatory therapy within 6 months before vaccination.
Exclusion Criteria:
Participants will be excluded if they meet any of the following criteria
- Previous receipt of any RSV vaccine.
- RSV infection diagnosed within the past 12 months.
- History of a severe allergic reaction to any component of the RSV vaccine.
- Moderate or severe acute illness at the time of screening.
- Pregnancy, planned pregnancy, or breastfeeding.
- Any underlying medical condition for which intramuscular injection is contraindicated.
- Any other condition that, in the investigator's judgment, may make the participant unsuitable for evaluation of immune responses.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Lung transplant recipient
Lung transplant recipients aged ≥19 years receiving immunosuppressive therapy (n=60) |
One dose of RSVPreF3 (Arexvy®) vaccine |
|
Comparatore attivo: Control
Immunocompetent adults aged ≥60 years (n=20) |
One dose of RSVPreF3 (Arexvy®) vaccine |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
Lasso di tempo: 1 month after vaccination
|
Geometric mean fold rise (GMFR) in RSV-A neutralizing antibody titers from pre-vaccination to 1 month after vaccination, compared between lung transplant recipients and immunocompetent adults. |
1 month after vaccination
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
Lasso di tempo: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-A neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Lasso di tempo: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-B neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Lasso di tempo: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-A neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Lasso di tempo: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-B neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Lasso di tempo: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in RSVPreF3-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Lasso di tempo: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in pan-RSV-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Lasso di tempo: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSVPreF3-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Lasso di tempo: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in pan-RSV-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (serologic response rate)
Lasso di tempo: 1 month, 12 months after vaccination
|
Proportion of participants with a ≥4-fold increase in antibody levels from pre-vaccination levels |
1 month, 12 months after vaccination
|
|
Cell mediated immunity
Lasso di tempo: 1 month, 12 months after vaccination
|
Frequency of RSV F-specific CD4+ and CD8+ T cells following stimulation with RSV F peptide pools, measured by flow cytometry. |
1 month, 12 months after vaccination
|
|
Safety (solicited adverse events)
Lasso di tempo: 7 days, 30 days after vaccination
|
Proportion of participants experiencing solicited local and systemic adverse events following vaccination. |
7 days, 30 days after vaccination
|
|
Safety (unsolicited adverse events, serious adverse events)
Lasso di tempo: Up to 12 months after vaccination
|
Proportion of participants experiencing unsolicited adverse events or serious adverse events following vaccination. |
Up to 12 months after vaccination
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Nam Joong Kim, M.D., PhD., Seoul National University Hospital
Pubblicazioni e link utili
Pubblicazioni generali
- Walsh EE, Perez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Ramet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B; RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5.
- Tan CS, Anjan S, Ariza-Heredia EJ, Magana F, Minniear TD, Kaur D, Falck-Ytter Y, Baden L. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients. Clin Infect Dis. 2026 Aug 24;82(Suppl 3):i123-i128. doi: 10.1093/cid/ciag117.
- Mayer EF, Falsey AR, Wolfe CR, Herc E, Burns F, Kabbani D, Kumar D, Mannan A, She F, Lan L, McGrath S, Kapoor A, Priddy F. Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345. Clin Infect Dis. 2026 May 20;82(5):e1112-e1121. doi: 10.1093/cid/ciag108.
- Levy L, Yahav D, Benzimra M, Bezalel Y, Hoffman T, Shirin N, Sinai T, Jurkowicz M, Deri O, Matalon N, Saute M, Lustig Y, Nachum E, Peled M, Nemet I, Mandelboim M. Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains. Vaccines (Basel). 2025 Apr 11;13(4):398. doi: 10.3390/vaccines13040398.
- Ferguson M, Schwarz TF, Nunez SA, Rodriguez-Garcia J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Grosskopf J, Voors-Pette C, Mehta H, Hailemariam HA, de Heusch M, Salaun B, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, Hulstrom V; RSV OA=ADJ-018 Study Group. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to >/=60 Years of Age. Clin Infect Dis. 2024 Oct 15;79(4):1074-1084. doi: 10.1093/cid/ciae364.
- Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, Ortega-Sanchez IR, Broder KR, Talbot HK, Long SS, Havers FP, Melgar M. Use of Respiratory Syncytial Virus Vaccines in Adults Aged >/=60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702. doi: 10.15585/mmwr.mm7332e1.
- Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, Havers FP. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. doi: 10.15585/mmwr.mm7229a4.
- Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrom V; AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
- Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. J Infect Dis. 2020 Sep 14;222(8):1298-1310. doi: 10.1093/infdis/jiaa361.
- Na SH, Jo HJ, Park JJ, Seo Y, Lee J, Bae J, Lee M, Lee CM, Kang CK, Choe PG, Park WB, Kim NJ. Comparison of clinical characteristics and outcomes in hospitalized adult patients infected with respiratory syncytial virus and influenza virus. Infect Dis (Lond). 2025 Feb;57(2):159-166. doi: 10.1080/23744235.2024.2402914. Epub 2024 Sep 16.
- de Zwart A, Riezebos-Brilman A, Lunter G, Vonk J, Glanville AR, Gottlieb J, Permpalung N, Kerstjens H, Alffenaar JW, Verschuuren E. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. Clin Infect Dis. 2022 Jul 6;74(12):2252-2260. doi: 10.1093/cid/ciab969.
- Havers FP, Whitaker M, Melgar M, Chatwani B, Chai SJ, Alden NB, Meek J, Openo KP, Ryan PA, Kim S, Lynfield R, Shaw YP, Barney G, Tesini BL, Sutton M, Talbot HK, Olsen KP, Patton ME; RSV-NET Surveillance Team. Characteristics and Outcomes Among Adults Aged >/=60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus - RSV-NET, 12 States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 6;72(40):1075-1082. doi: 10.15585/mmwr.mm7240a1.
- Tin Tin Htar M, Yerramalla MS, Moisi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020 Feb 13;148:e48. doi: 10.1017/S0950268820000400.
- Solidoro P, Curtoni A, Minuto S, Shbaklo N, De Rosa FG, Bondi A, Sidoti F, Patrucco F, Zanotto E, Corcione S, Boffini M, Marro M, Costa C, Rinaldo RF. Impact of RSV Infection in Transplant and Immunocompromised Population: Incidence and Co-Infections: Retrospective Analysis of a Single Centre. J Clin Med. 2025 Jul 7;14(13):4803. doi: 10.3390/jcm14134803.
- Mahan LD, Points A, Mohanka MR, Bollineni S, Joerns J, Kaza V, La Hoz RM, Gao A, Zhang S, Torres F, Banga A. Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. Transpl Infect Dis. 2021 Aug;23(4):e13661. doi: 10.1111/tid.13661. Epub 2021 Jun 22.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2608-187-1775
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
We are not planning to share IPDs publically, but de-identified individual participant data for all outcome measures could be shared with other researchers under their request.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .